DARE BIOSCIENCE INC. - COMMON STOCK

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

10 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

01 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

24 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

13 Nov 2025 16:01:00 By Nasdaq GlobeNewswire

Daré Bioscience Highlights Commercial Launch Readiness for DARE to PLAY™ Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women’s Sexual Health

11 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

06 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

03 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

06 Oct 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

24 Sep 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

14 Aug 2025 16:01:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

07 Aug 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

29 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

21 Jul 2025 13:47:42 By Nasdaq GlobeNewswire

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

21 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

14 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

11 Jul 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

12 Jun 2025 17:00:00 By Nasdaq GlobeNewswire

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream

04 Jun 2025 08:00:00 By Nasdaq GlobeNewswire

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

13 May 2025 16:01:00 By Nasdaq GlobeNewswire

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

06 May 2025 08:00:01 By Nasdaq GlobeNewswire